Overview
Global Cancer Technology is developing a unique, mechanistically distinct class of a potent, selective and brain penetrating modulator of PI3K. The compound:
- Is a potent and selective inhibitor
- Crosses the blood brain barrier
- Modulates immune cell function and inflammatory responses,
Its PI3K small molecule inhibitor has shown to induce growth arrest, increase immune recognition and increase sensitivity to radiation in cancer cells.
Management Team
JOHN CLARK
CEO & Founder
John Clark – is the founder, chairman and CEO of GCT with over 30 years of medical finance and business experience.
PETER HANSON
CFO
Peter Hanson – was formerly a partner with Ernst & Young and has over 35 years of experience as a CPA in finance and operations.
ROBERT PROULX
Senior Corporate Advisor
Robert Proulx – has held numerous Board positions, is a recognized thought leader in biopharma, and currently is the CEO of Imagion Biosystems.
Dr. K. NEWELL-ROGERS
Chief Scientific Consultant
M. Karen. Newell-Rogers – has held multiple board positions and multiple officer positions in biotechnology and is currently a Senior Research Professor in the Department of Medical Physiology in the School of Medicine at Texas A&M University.
MARK POTVIN
President
Mark Potvin – has 25 years in operations-primarily in medical device sales & marketing, engineering and supply chain strategies throughout the US and globally.
Scientific Advisors
SANTOSH KASARI, MD
Dr. EKOKOBE FONKEM
-Chairman at Neurology Department, Medical College Of Wisconsin
– Chief of Neuro Oncology at Baylor Scot & White Temple, Texas
SADIK ESENER, PhD
Director of the Cancer Early Detection Advanced Research center and Wendt Family Endowed Chair; Internationally known expert in photonics and opto-electronics.
WOLF RASIDIO, PhD
Organic Chemist from San Diego State University & University of Erlangen. Highly experienced polymer and organic chemist. Head of the Chemical Biology Program at the Moore’s Cancer Center at the UC San Diego School of Medicine and a Research Scientist in the Department of Neuroscience.
Traci Lyons
PhD Associate Professor, Medicine-Medical Oncology
Associate Professor, Medicine-Medical Oncology at the University of Colorado with a deep background focusing on mechanisms of lymphatic mediated metastasis of breast cancer. Specifically, utilizing mouse models to investigate developmentally regulated programs of inflammation and lymphangiogenesis that are utilized in the adult mammary gland and may be hijacked by breast tumor cells.
Prof. Dr Michael Rossmanand
Professor
An expert in diagnostics, cell-based therapeutics, neuroscience and genomics. Professor Rossbach holds academic appointments at the National University of Singapore (NUS), at the German Institute of Science and Technology (TUM Asia) in Singapore (Biochemistry, Cell biology, and Bioorganic Chemistry), at INSEAD Management School (Entrepreneur-in- Residence) and is a professor and member of the Faculty of the Witten School of Management (Germany).
Partners and Progress
GCT has forged numerous partnerships to advance our efforts in cancer drug discovery with some of the brightest scientists in their respective fields.
We are proud to be collaborating with Dr. David J. Daniels, a Pediatric brain tumor neurosurgeon at the Mayo Clinic Rochester-Neurosurgery Department.
Dr. Daniels has a special interest in DIPG and has initiated pre-clinical trials using GCT-007. We are very encouraged by the DIPG IC50 results to date and look forward to continued pre-clinical testing with the department.
Global Cancer Technology is delighted to have begun pre-clinicaltesting at the University of Newcastle-Australia. We are doing this in collaboration with Matthew Dun PhD.
Dr Dun is a worldwide recognized expert in the field of PI3K inhibitors and their use in DIPG. DR. Dun has tested GCT-007 and found it comparable to Paxalisib, a small molecule PI3K inhibitor that is similar to GCT-007. This is noteworthy for Global Cancer Technology as Paxalisib is entering a phase 3 clinical trial. Additional pre-clinical trials are planned with Dr. Dun
Global Cancer Technology is completing final pre-clinical testing at the Medical College of Wisconsin, prior to entering a Phase 1 clinical trial at the College. We are doing this important work under the Direction of Ekokobe Fonkem DO, who is the chair of the Neurology Department. The Company hopes to enter a phase 1 clinical trial in late 2024.
Barrow Neurological Institute is an international leader in treating, researching, and educating brain and spinal diseases, conditions, and injuries. Performance of In-vivo tests and Clinical Trials
• Performance of In vivo tests and Clinical Trials
• Completed preclinical trials with glioblastoma cultures
• Commencing now animal studies
We are partnering with the Baylor College of Medicine to complete preclinical and animal studies using advanced glioblastoma cell lines. This program will be in a lab directed by Dr. Ali Jalali, a highly regarded research neurosurgeon.
• In vivo tests using BaylorScott&White’s advanced glioblastoma cell lines
• Animal studies
We are partnering with Brown University and Dr. Wafik El- Deiry to perform preclinical trials investigating the use of our drug with a children’s form of glioblastpoma known as DIPG. He is a Professor of Pathology and Laboratory Medicine, a Mencoff Family University Professor of Medical Science and Associate Dean for Oncologic Science.
We plan to complete final preclinical studies at the Texas A&M School of Veterinary Medicine and Biomedical Sciences (VMBS). The studies will evalulate the PK, PD properties of our compound and will entail a multi-species study.
Baylor Scott & White is one of the largest not-for-profit healthcare systems in the United States. It will be the site for our Phase I clinical trial for glioblastoma. Baylor Scott & White sees over 300 glioblastoma patients a year.
We have begun a collaboration with them to a novel glioblastoma biomarker that will help measure tumor response to therapeutics and even detect potential or actual relapse.
An Investment Opportunity
Global Cancer Technology is offering accredited investors and opportunity to acquire pre-IPO shares.
Investors should consider this as:
- an opportunity to participate in the offering ahead of the general public
- a possible purchase of pre-IPO shares at a price that’s below the intended IPO price
- a chance to yield higher returns in a successful IPO.
Please click on “Invest Now” button and contact the company for a complete disclosure statement and offering prospectus